Altmetric

The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review

File Description SizeFormat 
10.1007%2Fs40273-018-0631-8.pdfPublished version1.02 MBAdobe PDFView/Open
Title: The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review
Authors: Diamantopoulos, A
Wright, E
Vlahopoulou, K
Cornic, L
Schoof, N
Maher, TM
Item Type: Journal Article
Abstract: BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a debilitating condition with significant morbidity and poor survival. Since 2010, there has been increased activity in the development of treatments that aim to delay progression of the disease. OBJECTIVE: Our study involves a comprehensive review of the literature for evidence on health-related quality of life (HRQoL), healthcare resource use (HCRU) and costs, and an assessment of the burden of illness of the condition. METHODS: We carried out a systematic literature review (SLR) to identify economic evaluations and HRQoL studies. We searched EMBASE, MEDLINE and MEDLINE In Process for relevant studies from database origins to April 2017. Alongside the presentation of the study characteristics and the available evidence, we carried out a qualitative comparison using reference population estimates for HRQoL and national health expenditure for costs. RESULTS: Our search identified a total of 3241 records. After removing duplicates and not relevant articles, we analysed 124 publications referring to 88 studies published between 2000 and 2017. Sixty studies were HRQoL and 28 were studies on costs or HCRU. We observed an exponential growth of publications in the last 3-5 years, with the majority of the studies conducted in Europe and North America. Among the HRQoL studies, and despite regional differences, there was some agreement between estimates on the absolute and relative level of HRQoL for patients with IPF compared with the general population. Regarding costs, after adjustments for the cost years and currency, the suggested annual per capita cost of patients with IPF in North America was estimated around US$20,000, 2.5-3.5 times higher than the national healthcare expenditure. Additionally, studies that analysed patients with IPF alongside a matched control cohort suggested a significant increase in resource use and cost. CONCLUSION: The reviewed evidence indicates that IPF has considerable impact on HRQoL, relative to the general population levels. Furthermore, in studies of cost and resource use, most estimates of the burden were consistent in suggesting an excess cost for patients with IPF compared with a control cohort or the national health expenditure. This confirms IPF as a growing threat for public health worldwide, with considerable impact to the patients and healthcare providers.
Issue Date: 1-Jul-2018
Date of Acceptance: 1-Mar-2018
URI: http://hdl.handle.net/10044/1/57950
DOI: 10.1007/s40273-018-0631-8
ISSN: 1170-7690
Publisher: Springer Verlag
Start Page: 779
End Page: 807
Journal / Book Title: PharmacoEconomics
Volume: 36
Issue: 7
Copyright Statement: © The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Keywords: 11 Medical And Health Sciences
14 Economics
Health Policy & Services
Publication Status: Published
Conference Place: New Zealand
Online Publication Date: 2018-03-01
Appears in Collections:National Heart and Lung Institute
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commonsx